Seminar: Monoclonal antibodies - dawn of a new era

07 June 2012

Bird & Bird's renowned regulatory team are delighted to invite you to a seminar focusing on monoclonal antibodies.

MAbs have for a long time been the promise for cancer therapy and other therapeutical applications where traditional pharmaceuticals have not provided the solution. Now they have emerged as the state of the art therapy for the future. Due to their very nature, they pose different questions and issues than small molecule drugs that are common in the marketplace today.

This seminar will deal with the protection of the investment in MAbs from a regulatory and IP perspective, from the very inception until market launch. It will offer both a practical and a strategic approach for tackling these issues.

If you are unable to attend, please note that we will be recording this seminar as a webinar and it will be made available upon request. Please indicate on the RSVP form if you would like access to this.

If you wish to submit a question ahead of the seminar, for our speakers to answer, please indicate this over email. We will endeavour to answer all questions.

For further details please email Karla Fryer or call on +44 (0)20 7982 6517.

The programme

Coffee and registration


Welcome and introduction

Wouter Pors, Partner, The Netherlands


15.05 - 15.35
MAbs - How to protect them using patents and SPCs
Michael Alt, Partner, Germany

15.35 - 16.05
Infringement issues relating to MAbs
Trevor Cook, Partner, United Kingdom

16.05 - 16.35
New US biosimilar guidelines - compared to the EU
Liz Fuller, Partner, France

16.35 - 17.05
Update on the use of human cells and tissues, and on the Advanced Therapy Medicinal Products in Europe
Marc Martens, Partner, Belgium

17.05 - 17.35
An industry perspective
Frank Landolt, IP and Legal Counsel, Ablynx

17.35 - 18:00
Ask the experts - Q&A with the Panel

Canapés and drinks

18.00 - 20.00